Xin Lang Cai Jing·2025-12-18 15:41Core Viewpoint - The announcement from Junshi Bioscience indicates that shareholder Tan Ying Investment plans to reduce its stake by up to 20.53 million shares, representing 2% of the total share capital, through block trading between January 13, 2026, and April 10, 2026, due to fund duration and liquidity arrangements [1]. Group 1: Shareholder Actions - Tan Ying Investment currently holds 59.45 million shares, accounting for 5.79% of the total share capital [1]. - The initial holding of Tan Ying Investment was 71.45 million shares, which represented 6.96% of the total share capital [2]. - Since June 20, 2025, Tan Ying Investment has cumulatively reduced its holdings by 12 million shares, realizing approximately 526 million yuan [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Bioscience reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [3]. - As of September 30, 2025, the number of shareholders for Junshi Bioscience was 35,900, an increase of 15.17% from the previous period [3]. Group 3: Market Performance - As of the latest report, Junshi Bioscience's stock price has decreased by 1.42%, with a trading volume of 173 million yuan and a turnover rate of 0.63%, bringing the total market capitalization to 36.478 billion yuan [3]. - The stock has experienced a 30% increase year-to-date, but has seen declines of 2.15% over the last five trading days, 3.50% over the last 20 days, and 22.15% over the last 60 days [3].